Tirzepatide
Approved medicinePrimarily used for Type 2 Diabetes Mellitus & Obesity.
Also known as Mounjaro, Zepbound.
Recent clinical, regulatory, research and industry developments relating to this drug.
Tirzepatide Beats Semaglutide for Weight Loss, Not Safety
Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
Taltz, Zepbound combo yields sustained improvement at 1 year in psoriatic disease, obesity
1-Year Tirzepatide, Ixekizumab Combo Trial Results Reported
Indication expansion: TIRZEPATIDE (NDA215866)
Indication expansion: TIRZEPATIDE (NDA215866)
Indication expansion: TIRZEPATIDE (NDA217806)
Label change: TIRZEPATIDE (NDA217806)
GLP-1 and the cardiovascular system.
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
High point estimate, but substantial uncertainty remains.
— 10 supporting evidence families · 1 well-powered no-effect result
Confidence is moderated by well-powered no-effect evidence and limited publication incorporation, despite broad trial support.
High point estimate, but substantial uncertainty remains.
Confidence has a moderate point estimate but a wide uncertainty band — the evidence base is still thin.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as… Show full indicationShow less
Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes, obesity & metabolism7
- Cardiovascular diabetology2
- JAMA network open2
- Molecular metabolism2
- The Journal of clinical investigation2
- Cell metabolism1
- Coskun T4
- Nauck MA4
- Urva S4
- D'Alessio DA3
- Haupt A3
- Sloop KW3
- Alsina-Fernandez J2
- Barbieri M2
- College of Medicine2
- Duke University Medical Center2
- International Medical University2
- University of Campania "Luigi Vanvitelli"2
- University of Utah2
- "Attikon" University Hospital1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Tirzepatide, with 16 overlapping disease areas.
Acts on the same molecular target as Tirzepatide, with 11 overlapping disease areas.
Acts on the same molecular target as Tirzepatide, with 8 overlapping disease areas.
Acts on the same molecular target as Tirzepatide, with 5 overlapping disease areas.
Studied across 14 of the same disease areas as Tirzepatide in the shared literature.
Studied across 8 of the same disease areas as Tirzepatide in the shared literature.
Studied across 7 of the same disease areas as Tirzepatide in the shared literature.
Studied across 6 of the same disease areas as Tirzepatide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- Regulatory event sources are credited in the Regulatory Timeline above.